Inflammation as target in cancer therapy

Giulia Marelli, Antonio Sica, Luca Vannucci, Paola Allavena

Research output: Contribution to journalReview articlepeer-review

Abstract

Cells of the innate immunity infiltrating tumour tissues promote, rather than halt, cancer cell proliferation and distant spreading. Tumour-Associated Macrophages (TAMs) are abundantly present in the tumour milieu and here trigger and perpetrate a state of chronic inflammation which ultimately supports disease development and contributes to an immune-suppressive environment. Therapeutic strategies to limit inflammatory cells and their products have been successful in pre-clinical tumour models. Early clinical trials with specific cytokine and chemokine inhibitors, or with strategies designed to target TAMs, are on their way in different solid malignancies. Partial clinical responses and stabilization of diseases were observed in some patients, in the absence of significant toxicity. These encouraging results open new perspectives of combination treatments aimed at reducing cancer-promoting inflammation to maximize the anti-tumour efficacy.

Original languageEnglish
Pages (from-to)57-65
Number of pages9
JournalCurrent Opinion in Pharmacology
Volume35
DOIs
Publication statusPublished - Aug 1 2017

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Inflammation as target in cancer therapy'. Together they form a unique fingerprint.

Cite this